Sanofi to acquire Blueprint Medicines for $9.1bn.

Sanofi, a French multinational pharmaceutical and healthcare company, agreed to acquire Blueprint Medicines, a US-based, publicly traded biopharmaceutical company, for $9.1bn. "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders. It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions. We are excited to welcome Blueprint's talented people and we look forward to chasing the miracles of science together. This makes sense for science, for both companies, for healthcare professionals, and – most of all – for patients," Paul Hudson, Sanofi CEO.